Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Froehlich, EV; Scheipl, S; Lazary, A; Varga, PP; Schmid, C; Stammberger, H; Beham, A; Bodo, K; Schroettner, H; Quehenberger, F; Windhager, R; Liegl, B; Leithner, A.
Expression of Ezrin, MMP-9, and COX-2 in 50 Chordoma Specimens: A Clinical and Immunohistochemical Analysis.
Spine (Phila Pa 1976). 2012; 37(13):E757-E767
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Beham Alfred
Beham-Schmid Christine
Bodo Koppany
Fröhlich-Sorger Elke
Leithner Andreas
Liegl-Atzwanger Bernadette
Quehenberger Franz
Scheipl Susanne
Stammberger Heinz
Windhager Reinhard
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Study Design. Retrospective study. Objective. To investigate the immunohistochemical expression profile of ezrin, matrix metalloproteinase-9 (MMP-9), and cyclooxygenase-2 (COX)-2 in chordomas. Summary of Background Data. Ezrin, MMP-9, and COX-2 are expressed in different solid tumors, including chordomas. This study investigates the immunohistochemical expression of the aforementioned biomarkers and the clinical outcome in regard to immunohistochemistry, tumor volume, and localization. Methods. Fifty brachyury-verified chordoma specimens of 34 primary and 16 recurrent tumors of 44 patients were tested for ezrin, MMP-9, and COX-2 as possible therapeutical targets by immunohistochemistry. The clinical evaluation concentrated on tumor location, volume, and age-related data. Results. Ezrin expression was detected in 33 of 34 primary chordomas and in 16 of 16 recurrent cases. The primary chordomas located in the sacrum and the spine demonstrated a significantly higher percentage of positively stained tumor cells (P = 0.034) than the skull-based chordomas. An expression of MMP-9 and COX-2 was observed in 33 of 34 primary chordomas and in 16 of 16 recurrences, and in 13 of 34 primary chordomas and in 11 of 16 recurrences, respectively. Patients' survival was significantly influenced by age (P = 0.01), tumor location (P = 0.029), and tumor volume (P = 0.002). A signifi cant positive correlation between tumor volume and the anatomic distance of the chordoma from the skull was calculated (P = 0.00002). Conclusion. En bloc resection with tumor-free margins is seldom feasible, particularly in the sacrum. Intralesional excisions mostly end in early local recurrence; therefore, the demand for further treatment options is frequently posed. The marked trend of the investigated biomarkers of this study may build a starting point for further investigations as molecular targets for future adjuvant therapies in chordomas. Future multicenter studies on larger patients' series are necessary to elucidate these preliminary data and to test new treatment options for patients with chordomas.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Aged, 80 and over -
Chordoma - enzymology Chordoma - mortality Chordoma - secondary Chordoma - therapy
Cyclooxygenase 2 - analysis
Cytoskeletal Proteins - analysis
Female -
Humans -
Humans -
Immunohistochemistry -
Kaplan-Meier Estimate -
Male -
Matrix Metalloproteinase 9 - analysis
Middle Aged -
Neoplasm Recurrence, Local -
Predictive Value of Tests -
Prognosis -
Proportional Hazards Models -
Retrospective Studies -
Risk Assessment -
Risk Factors -
Skull Neoplasms - enzymology Skull Neoplasms - mortality Skull Neoplasms - pathology Skull Neoplasms - therapy
Spinal Neoplasms - enzymology Spinal Neoplasms - mortality Spinal Neoplasms - pathology Spinal Neoplasms - therapy
Time Factors -
Tumor Burden -
Tumor Markers, Biological - analysis
Young Adult -

Find related publications in this database (Keywords)
chordoma
immunohistochemistry
brachyury
ezrin
MMP-9
COX-2
location-
age-
volume-dependent survival
© Meduni Graz Impressum